JNJ is the ticker symbol for JOHNSON & JOHNSON, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks JNJ with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is JNJ a good stock to buy?

13F Pro's AI ranking engine scores JNJ at 69.2/100, ranked #265 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for JNJ is available at https://13fpro.ai/company/JNJ. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source JNJ data?

All JOHNSON & JOHNSON fundamentals and ownership data come directly from SEC EDGAR. JOHNSON & JOHNSON files with the SEC under CIK 200406. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

JOHNSON & JOHNSON JNJ

NYSEMega CapHealthcare

13F Pro quality score

Rank #265 of 2,925TOP 10%

Why it scores 69 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$25.40B

Quarter to Sep 27

Net income

$210.00M

Quarter to Sep 27

Free cash flow

$6.36B

Quarter to Sep 27

Operating margin

0.1%

Quarter to Sep 27

Top Institutional Holders

as of Q2 2026

$456.39B total

BlackRock, Inc.

$53.87B-0.6%

VANGUARD CAPITAL MANAGEMENT LLC

$39.93B+0.4%

STATE STREET CORP

$33.98B+0.2%

VANGUARD PORTFOLIO MANAGEMENT LLC

$16.35B+1.3%

JPMORGAN CHASE & CO

$15.07B-7.6%

GEODE CAPITAL MANAGEMENT, LLC

$14.97B-0.1%

MORGAN STANLEY

$11.38B+0.2%

NORGES BANK

$8.08B--

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

$8.02B0.0%

NORTHERN TRUST CORP

$7.31B-1.8%

BANK OF AMERICA CORP /DE/

$5.95B-8.1%

PRICE T ROWE ASSOCIATES INC /MD/

$5.84B+39.4%

FMR LLC

$5.74B-8.8%

WELLINGTON MANAGEMENT GROUP LLP

$5.74B+12.5%

Bank of New York Mellon Corp

$5.51B-0.6%

GOLDMAN SACHS GROUP INC

$5.01B+9.2%

Legal & General Group Plc

$4.90B-0.3%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$4.86B-0.3%

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME

$4.68B-6.2%

WELLS FARGO & COMPANY/MN

$4.41B+2.7%

Invesco Ltd.

$3.98B+4.2%

DEUTSCHE BANK AG\

$3.98B+8.5%

DIMENSIONAL FUND ADVISORS LP

$3.91B-2.8%

Capital World Investors

$3.86B+29.5%

VANGUARD FIDUCIARY TRUST CO

$3.43B-0.3%

See all 4,715 institutional holders →

What's Driving JNJ's Business? Latest 10-Q Breakdown

16/16 datapoints verified

AI-extracted from the 10-Q filed 2026-10-21 — Q3 FY2026 (quarter ended September 27, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

J&J's fiscal third-quarter sales rose 5.9% to $25.4B, but net earnings fell to $210M from $5.2B as a $5.5B talc ovarian litigation accrual hit other expense.

Biggest Revenue Drivers

Innovative Medicine$16.8B+7.7% YoY

Growth driven by Oncology (DARZALEX, CARVYKTI) and Neuroscience (SPRAVATO, CAPLYTA) and Immunology TREMFYA, partially offset by STELARA biosimilar erosion.

MedTech$8.6B+2.5% YoY

Growth in Cardiovascular (Electrophysiology, Shockwave) and Vision, partially offset by Surgery operational decline.

Biggest Revenue Drivers

Total revenue: $25.4B+5.9% YoY

Innovative Medicine$16.8B+7.7% YoY

Growth driven by Oncology (DARZALEX, CARVYKTI) and Neuroscience (SPRAVATO, CAPLYTA) and Immunology TREMFYA, partially offset by STELARA biosimilar erosion.

Within Innovative Medicine

DARZALEX$4.2B+15.4% YoY

Driven by strong share gains and market growth.

TREMFYA$2.4B+68.3% YoY

Share gains across all indications with significant IBD launch momentum and market growth.

MedTech$8.6B+2.5% YoY

Growth in Cardiovascular (Electrophysiology, Shockwave) and Vision, partially offset by Surgery operational decline.

Largest Expense Items

Research & development$4.7B+26.7% YoY

Increase driven primarily by acquired in-process R&D of approximately $1.0B from the Firefly Bio acquisition.

Other (income) expense, net$5.8Bvs. $(0.5)B income in prior year

Primarily a $5.5B charge related to the proposed talc ovarian litigation resolution, plus $0.3B Orthopaedics separation costs and $0.3B Sail Biomedicines option premium.

Cost of products sold$8.1B31.9% of sales vs. 30.4%

Unfavorable product mix from STELARA decline and higher CAPLYTA intangible amortization, partially offset by ~$0.2B MedTech tariff recoveries.

Margins: Gross margin fell to 68.1% from 69.6% on unfavorable product mix and higher amortization. Pre-tax earnings were $34M (0.1% of sales) versus 31.2% a year earlier, driven mainly by the talc charge and R&D/other items.

Watch Items from the Filing

Proposed talc ovarian resolution requires $5.5B commitment; total talc reserve is approximately $9.0B present value, with ~76,500 U.S. plaintiffs pending.
STELARA sales fell 54.4% in the quarter due to biosimilar competition, with a negative ~4.2% impact on worldwide operational sales growth.
Planned Orthopaedics separation expected mid-2027, with separation costs of $0.4B in the quarter and $0.7B year-to-date.
Potential generic entrants in 2027 for OPSUMIT/OPSYNVI, UPTRAVI, and XARELTO in the U.S. are expected to reduce future sales.
Operational U.S. Innovative Medicine sales grew 11.1% in the quarter, led by TREMFYA (+79.1% U.S.) and oncology launches.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q3 2026

EDGAR

Net Income

Q3 2026

EDGAR

EPS (Diluted)

Q3 2026

EDGAR

Operating Margin

Q3 2026

EDGAR

ROIC

Q3 2026

EDGAR

Free Cash Flow

Q3 2026

EDGAR

Debt/Equity

Q3 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/JNJ

Earnings Per Share

13fpro.ai/company/JNJ

Loading ratio trend…

JOHNSON & JOHNSON reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$94.2B	$26.8B	34.6%
FY 2024	10-K	$88.8B	$14.1B	18.8%
FY 2023	10-K	$85.2B	$35.2B	17.7%
FY 2022	10-K	$80.0B	$17.9B	24.2%
FY 2021	10-K	$78.7B	$20.9B	24.4%
FY 2020	10-K	$82.6B	$14.7B	20.0%

About JOHNSON & JOHNSON (JNJ): stock profile, AI score and financials

JOHNSON & JOHNSON (JNJ) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores JNJ at 69.2/100 on a composite quality score built from its SEC filings, placing it at rank #265 of 2,925 stocks — the top 10% of the AI-ranked universe. JNJ scores in the top quartile across revenue scale (98.6), balance sheet strength (81.3), earnings quality (77.5). Shareholder dilution risk is elevated at 46.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), JOHNSON & JOHNSON reports quarterly revenue of $25.4B, net income of $210.0M, an operating margin of 0.1%. Top institutional holders of JNJ by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. JNJ trades on the NYSE exchange and files with the SEC under CIK 200406. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JNJ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for JOHNSON & JOHNSON directly from SEC EDGAR.

Financials through the period ended Sep 27, 2026SEC EDGAR: CIK 200406 →

JOHNSON & JOHNSON JNJ

Top Institutional Holders

What's Driving JNJ's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

JNJ key financials by period

JNJ insiders

Congress trading in JNJ

About JOHNSON & JOHNSON (JNJ): stock profile, AI score and financials

JOHNSON & JOHNSON JNJ

Top Institutional Holders

What's Driving JNJ's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

JNJ key financials by period

Companies similar to JNJ

JNJ insiders

Congress trading in JNJ

About JOHNSON & JOHNSON (JNJ): stock profile, AI score and financials